FDMT – 4d molecular therapeutics, inc. (US:NASDAQ)
Stock Stats
News
4DMT to Participate in Upcoming Investor Conferences
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "sell (e+)" rating re-affirmed by analysts at Weiss Ratings.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Bank of America Co. from $42.00 to $40.00. They now have a "buy" rating on the stock.
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD [Yahoo! Finance]
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD
Form EFFECT 4D Molecular Therapeutic
Form 4 4D Molecular Therapeutic For: Mar 06 Filed by: Bizily Scott
Form 4 4D Molecular Therapeutic For: Mar 06 Filed by: Kirn David
Form 4 4D Molecular Therapeutic For: Mar 06 Filed by: Mehra Uneek
Form 4 4D Molecular Therapeutic For: Mar 06 Filed by: Kim Robert Young
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.